A patient with a rare combination of prolactinoma and aldosterone producing adrenal adenoma (APA) was reported in relation to studies concerning dopaminergic regulation of PRL and aldosterone secretion. The patient is a 38-year-old female with plasma PRL and aldosterone concentrations (PAC) of 563 ng/ml and 54 ng/dl, respectively. A bolus of 10 mg of metoclopramide significantly increased plasma PRL in 6 normal subjects and in 4 patients with APA, whereas the responses were blunted in 7 patients with prolactinoma and in our patient. The response of aldosterone to metoclopramide was less than that of PRL, but similar in all studied subjects, indicating that the dopaminergic inhibition of aldosterone secretion is less than that of PRL in normal subjects and did not change in patients with APA or prolactinoma. Oral administration of 2.5 mg of bromocriptine suppressed plasma PRL significantly in all the subjects studied, but did not produce any consistent changes in PAC. Discrepancies in the response of PRL and aldosterone to metoclopramide and to bromocriptine suggest a difference in the dopaminergic regulation of PRL and aldosterone secretion in both normal subjects and patients with prolactinoma and APA. It is unlikely that reduced dopaminergic inhibition is the basis for hypersecretion of PRL and aldosterone in our patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1507/endocrj1954.39.169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic advances in COVID-19.
Nat Rev Nephrol
January 2023
Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed millions of lives. Unlike the early days of the pandemic, when management decisions were based on extrapolations from in vitro data, case reports and case series, clinicians are now equipped with an armamentarium of therapies based on high-quality evidence. These treatments are spread across seven main therapeutic categories: anti-inflammatory agents, antivirals, antithrombotics, therapies for acute hypoxaemic respiratory failure, anti-SARS-CoV-2 (neutralizing) antibody therapies, modulators of the renin-angiotensin-aldosterone system and vitamins.
View Article and Find Full Text PDFMachine learning for classification of hypertension subtypes using multi-omics: A multi-centre, retrospective, data-driven study.
EBioMedicine
October 2022
Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee DD2 4BF, UK; Institute of Health & Wellbeing, University of Glasgow, Glasgow G12 8RZ, UK. Electronic address:
Background: Arterial hypertension is a major cardiovascular risk factor. Identification of secondary hypertension in its various forms is key to preventing and targeting treatment of cardiovascular complications. Simplified diagnostic tests are urgently required to distinguish primary and secondary hypertension to address the current underdiagnosis of the latter.
View Article and Find Full Text PDFCardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Metabolism
January 2022
Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease (CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP control were the cornerstones for preventing progression of CKD and CV disease associated with T2D. However, there has been a paradigm shift in treatment since the publication of the first clinical trial demonstrating benefits of sodium glucose cotransporter 2 (SGLT2) inhibitors in 2015.
View Article and Find Full Text PDFTwo novel heterozygous mutations in the CYP17A1 gene in a Chinese patient with 17α-hydroxylase 17,20-lyase deficiency.
Discov Med
December 2018
Department of Endocrinology, Shandong Provincial Hospital affiliated to Shandong University, Jinan, Shandong, China.
Congenital adrenal hyperplasia (CAH) resulting from 17α-hydroxylase/17,20-lyase deficiency (17-OHD) is an uncommon autosomal recessive disease. 17-OHD is caused by mutations in the cytochrome P450c17 gene (CYP17A1), and characterized by hypertension, hypokalemia, female sexual infantilism, or male pseudohermaphroditism. Here we report a case of a 19-year-old Chinese girl (46,XX) with 17-OHD, and analyze her clinical and molecular genetic characteristics.
View Article and Find Full Text PDFCoexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?
J Clin Endocrinol Metab
September 2015
Medizinische Klinik und Poliklinik IV (T.A.W., A.S.D., A.R., E.F., M.B., J.S., F.B., M.R.) and Klinische Radiologie (M.Tr., L.G.), Klinikum der Ludwig-Maximilians-Universität München, 80336 Munich, Germany; Division of Internal Medicine and Hypertension (T.A.W., J.B., F.V., P.M.), Department of Medical Sciences, University of Turin, 10126 Turin, Italy; and Department of Endocrinology (M.Th.), Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Context: Coexisting prolactinoma-primary aldosteronism (PA) is infrequently reported.
Objective: The objective of the study was to identify patients with prolactinoma-PA and test the hypothesis that elevated prolactin (PRL) concentrations play a role in PA pathogenesis.
Setting And Design: Hyperprolactinemia/prolactinoma was diagnosed in PA patients from two referral centers (Munich, Germany, and Turin, Italy) and in essential hypertensive (EH) patients from one center (Turin).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!